Urinary Incontinence Market Size, Share & Trend Analysis - Global - 2025-2031 - Includes: Urethral Bulking Agent Market, Incontinence Sling Market and 2 more
Description
Global Urinary Incontinence Device Market Report, 2025 Edition
Executive Summary
The global urinary incontinence device market was valued at over 886 million dollars in 2024. The market is expected to grow at a 4.4 percent CAGR to reach over 1.2 billion dollars by 2031. Urinary incontinence is a highly prevalent condition that affects both men and women worldwide. Incidence rates increase significantly with age and are amplified by chronic disease, pelvic floor dysfunction, childbirth history, prostate disease and neurological conditions.
This report covers the global market for urethral bulking agents, female urinary incontinence slings, male implantable devices and urinary bags. Each segment is analyzed by device type and procedure volume. The female sling market is segmented into transvaginal tape slings, transobturator slings and single-incision slings. The male implantable device market is segmented into male slings and artificial urinary sphincters. Urinary bags are segmented into bedside and leg bags.
The report quantifies units sold, average selling prices, growth rates, competitive shares and procedure volumes. It evaluates market drivers such as demographic aging, lifestyle shifts and increased acceptance of urethral bulking agents, as well as market limiters including regulatory constraints, reimbursement changes, procedural concerns and litigation affecting sling products.
Historical data for 2021 through 2024 is included, with forecasts through 2031. The scope reflects how urologists and gynecologic surgeons evaluate treatment options, adoption trends and technology innovations across all major global regions.
Market Overview
Urinary incontinence affects millions of patients worldwide. The condition becomes increasingly common with age. By 2030, many countries will see record-high percentages of older adults, leading to higher demand for incontinence treatments. Incontinence impacts quality of life, independence, emotional well-being and physical activity. As awareness improves, more patients seek treatment rather than managing symptoms alone.
The global urinary incontinence device market includes a wide range of treatment options that vary by severity, patient preference, underlying pathology and recovery time. Urethral bulking agents provide a minimally invasive alternative to slings, especially for patients who want short recovery times or who cannot undergo mesh-based procedures. Female slings remain an important treatment option, though procedure volume has fluctuated due to safety concerns, regulatory actions and public awareness. Male implantable devices offer effective long-term solutions for men with sphincter dysfunction, often related to prostate surgery. Urinary bags provide support for patients managing incontinence at home, during recovery periods or after surgery.
The female incontinence sling market includes multiple sling types that differ in insertion path and fixation. Transvaginal tape slings support mid-urethral placement through a retropubic route. Transobturator slings use a lateral route that avoids the retropubic space. Single-incision slings, also called mini-slings, offer shorter incisions and faster recovery, though regulatory scrutiny has influenced product availability in some markets.
Male devices include male slings and artificial urinary sphincters. Male slings are typically used for mild to moderate incontinence. Artificial urinary sphincters are used for severe incontinence and remain the gold standard for patients with significant sphincter damage.
Urinary bags remain essential for patients using external catheters, patients recovering from major surgery and those with severe leakage. Bedside bags are used in hospitals and long-term care facilities, while leg bags support outpatient and homecare mobility.
In recent years, regulatory actions, litigation surrounding mesh sling safety and public concern regarding adverse events have influenced procedural volume and reduced adoption of certain sling products, especially in developed markets. At the same time, these challenges have contributed to growth in alternative therapies such as urethral bulking agents, which have gained traction as a result.
The global market reflects the balance between rising clinical demand, patient preference for minimally invasive solutions, safety concerns regarding mesh implants and a broadening demographic affected by incontinence.
Market Drivers
Demographic Factors
Demographic aging is one of the most significant drivers of the urinary incontinence device market. Urinary incontinence becomes more common with age due to comorbidities, weakened pelvic muscles, hormonal changes, neurological conditions and mobility limitations. Women experience high rates of urinary incontinence after menopause, and prevalence increases steadily throughout older adulthood. Studies report urinary incontinence in one-third of women aged 60 to 90.
Prevalence estimates vary by region, ranging from 1.8 to 30.5 percent in Europe, 1.7 to 36.4 percent in the United States and 1.5 to 15.2 percent in Asia.
Global aging trends are rapidly accelerating.
In the United States, 17 percent of the population was over 65 in 2020.
In Europe’s Big 5 countries, the percentage of adults over 60 is expected to reach between 25 and 42 percent by 2050.
China’s population over 60 is projected to exceed 30 percent by 2030.
Japan is one of the oldest populations in the world, with one-third of residents expected to be 65 or older by 2040.
Brazil’s population aged 60 and older is expected to reach nearly 34 percent by 2060.
Russia is also aging but at a slower pace.
As these demographic shifts unfold, the number of patients requiring both non-surgical and surgical incontinence treatments will grow substantially. This will increase demand for urethral bulking agents, male implantable devices, female slings and urinary bags.
Active Lifestyles
While urinary incontinence is most common in adults over the age of 50, a rising number of younger patients are being diagnosed. Changes in lifestyle, childbirth patterns, pelvic floor injuries, sports participation and increased awareness all contribute to higher diagnosis rates.
Many patients prefer solutions that allow them to maintain active lifestyles. Absorbent pads are not suitable for long-term use among active individuals. As a result, demand for minimally invasive treatments such as urethral bulking agents and selected implantable devices continues to increase.
Male external catheters, female slings and minimally invasive bulking agents are preferred by patients who want to remain active without prolonged recovery times. This trend is expected to strengthen as more patients prioritize mobility and quality of life.
Growth of Urethral Bulking Agents
Urethral bulking agents are minimally invasive treatments that provide a viable alternative to slings for both male and female patients. These procedures can be performed quickly and do not require mesh, which is important for patients concerned about implantable materials.
Bulkers have gained interest due to concerns surrounding vaginal slings, regulatory actions and public attention to implant safety. As patient and clinician awareness increases, bulking agents are expected to experience strong growth and take share from sling procedures in certain markets.
Market Limiters
Regulatory and Reimbursement Changes
The urinary incontinence device market has been significantly affected by litigation, product recalls and regulatory scrutiny. These factors have impacted sling procedures most severely.
Notable examples include:
In 2017, a class action suit was launched in Australia against Johnson & Johnson and Ethicon concerning transvaginal mesh.
More than 5,000 lawsuits regarding transvaginal mesh remain pending globally.
In 2018, the Australian Register of Therapeutic Goods removed transvaginal mesh for pelvic organ prolapse repair and mini-slings from the market. This included Solyx and Altis devices.
In July 2018, the NHS suspended the use of urinary incontinence slings, reducing demand significantly in the United Kingdom and raising global awareness.
These developments led many clinicians to take a more conservative approach to sling selection, which slowed procedure volumes and decreased market growth across several European regions.
Procedural Limitations
Female sling procedures involve surgical intervention, including insertion of mesh material that may complicate future childbirth. Active patients who cannot commit to six to eight weeks of recovery may choose bulking agents, radiofrequency treatments or laser devices instead of sling surgery.
Male sling and artificial urinary sphincter procedures also require recovery time and patient training, which may limit adoption among certain patient groups.
Autologous Pubovaginal Slings
Some patients prefer to avoid synthetic mesh entirely. In these cases, surgeons may harvest autologous tissue from the patient’s abdomen and use it as a sling. This eliminates concerns about mesh implants but increases procedure complexity and cost.
Autologous procedures reduce the use of synthetic sling products and create a natural alternative that shifts some procedural volume away from commercial sling devices.
Market Coverage and Data Scope
Quantitative Coverage
Market size
Market shares
Market forecasts
Growth rates
Units sold
Average selling prices
Qualitative Coverage
Growth trends
Market limiters
Competitive analysis and SWOT
Company profiles and portfolios
Mergers and acquisitions
FDA recalls and regulatory developments
Disruptive technologies
Disease and demographic overviews
Time Frame
Historical data from 2021 to 2024
Base year 2024
Forecasts to 2031
Data Sources
Primary interviews with urologists and gynecologists
Government physician and hospital datasets
Regulatory filings
Hospital private data
Import and export data
iData internal modeling and procedure databases
Markets Covered and Segmentation
Urethral Bulking Agent Market
Female Urinary Incontinence Sling Market
Transvaginal tape slings
Transobturator slings
Single-incision slings
Male Implantable Device Market
Male incontinence slings
Artificial urinary sphincters
Urinary Bag Market
Bedside bags
Leg bags
Competitive Analysis
Boston Scientific
Boston Scientific was the leading competitor in the global urinary incontinence device market in 2024. The company held top positions in both urethral bulking agents and female incontinence slings. Boston Scientific’s leadership reflects a broad product portfolio, strong branding and continued investment in products that support minimally invasive therapy. The company’s innovations and market reach have helped maintain its position across major regions.
Coloplast
Coloplast held the second-largest share of the total market in 2024. Coloplast offers a wide range of female urinary slings such as Aris and Altis, as well as the Virtue male sling. The company is active in both male and female implantable incontinence devices and has a strong reputation for quality and clinical training support. Coloplast has a sizable presence across Europe and North America, contributing to its global position.
Ethicon
Ethicon was the third-leading competitor and maintained a strong presence in the female urinary sling market. Following the closure of Astora, Ethicon expanded its leadership position in female sling products and remains a key supplier. Ethicon does not participate in the male implantable device market but remains influential in female procedures due to its broad distribution network and established product line.
Technology and Practice Trends
Key trends shaping the urinary incontinence device market include:
Increasing adoption of minimally invasive bulking agents as an alternative to mesh slings
Continued use of slings where regulatory frameworks allow, with gradual shifts to slings with improved safety profiles
Broader availability of male external and implantable devices for men who desire improved quality of life
Growth of compact urinary bags designed for discreet daily use
Higher focus on patient-centered solutions, including devices that support active lifestyles
Increased reliance on autologous slings in specific patient populations concerned about synthetic mesh
Technology improvements in bulking agents, including longer-lasting injectable materials
Market developments continue to reflect patient preference for comfort, reduced recovery time and long-term treatment efficacy.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
Which urinary incontinence segments will grow fastest through 2031
How demographic aging and lifestyle trends are reshaping global demand
What impact regulatory actions have had on sling procedure volumes
How urethral bulking agents are positioned to gain share as alternatives to mesh
Which competitors hold the strongest positions and why
How reimbursement and product safety concerns will shape future market adoption
Where global regions differ in clinical practice and purchasing decisions
This report supports strategic planning, product development, market entry and competitive analysis within the urinary incontinence device sector.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows.
Executive Summary
The global urinary incontinence device market was valued at over 886 million dollars in 2024. The market is expected to grow at a 4.4 percent CAGR to reach over 1.2 billion dollars by 2031. Urinary incontinence is a highly prevalent condition that affects both men and women worldwide. Incidence rates increase significantly with age and are amplified by chronic disease, pelvic floor dysfunction, childbirth history, prostate disease and neurological conditions.
This report covers the global market for urethral bulking agents, female urinary incontinence slings, male implantable devices and urinary bags. Each segment is analyzed by device type and procedure volume. The female sling market is segmented into transvaginal tape slings, transobturator slings and single-incision slings. The male implantable device market is segmented into male slings and artificial urinary sphincters. Urinary bags are segmented into bedside and leg bags.
The report quantifies units sold, average selling prices, growth rates, competitive shares and procedure volumes. It evaluates market drivers such as demographic aging, lifestyle shifts and increased acceptance of urethral bulking agents, as well as market limiters including regulatory constraints, reimbursement changes, procedural concerns and litigation affecting sling products.
Historical data for 2021 through 2024 is included, with forecasts through 2031. The scope reflects how urologists and gynecologic surgeons evaluate treatment options, adoption trends and technology innovations across all major global regions.
Market Overview
Urinary incontinence affects millions of patients worldwide. The condition becomes increasingly common with age. By 2030, many countries will see record-high percentages of older adults, leading to higher demand for incontinence treatments. Incontinence impacts quality of life, independence, emotional well-being and physical activity. As awareness improves, more patients seek treatment rather than managing symptoms alone.
The global urinary incontinence device market includes a wide range of treatment options that vary by severity, patient preference, underlying pathology and recovery time. Urethral bulking agents provide a minimally invasive alternative to slings, especially for patients who want short recovery times or who cannot undergo mesh-based procedures. Female slings remain an important treatment option, though procedure volume has fluctuated due to safety concerns, regulatory actions and public awareness. Male implantable devices offer effective long-term solutions for men with sphincter dysfunction, often related to prostate surgery. Urinary bags provide support for patients managing incontinence at home, during recovery periods or after surgery.
The female incontinence sling market includes multiple sling types that differ in insertion path and fixation. Transvaginal tape slings support mid-urethral placement through a retropubic route. Transobturator slings use a lateral route that avoids the retropubic space. Single-incision slings, also called mini-slings, offer shorter incisions and faster recovery, though regulatory scrutiny has influenced product availability in some markets.
Male devices include male slings and artificial urinary sphincters. Male slings are typically used for mild to moderate incontinence. Artificial urinary sphincters are used for severe incontinence and remain the gold standard for patients with significant sphincter damage.
Urinary bags remain essential for patients using external catheters, patients recovering from major surgery and those with severe leakage. Bedside bags are used in hospitals and long-term care facilities, while leg bags support outpatient and homecare mobility.
In recent years, regulatory actions, litigation surrounding mesh sling safety and public concern regarding adverse events have influenced procedural volume and reduced adoption of certain sling products, especially in developed markets. At the same time, these challenges have contributed to growth in alternative therapies such as urethral bulking agents, which have gained traction as a result.
The global market reflects the balance between rising clinical demand, patient preference for minimally invasive solutions, safety concerns regarding mesh implants and a broadening demographic affected by incontinence.
Market Drivers
Demographic Factors
Demographic aging is one of the most significant drivers of the urinary incontinence device market. Urinary incontinence becomes more common with age due to comorbidities, weakened pelvic muscles, hormonal changes, neurological conditions and mobility limitations. Women experience high rates of urinary incontinence after menopause, and prevalence increases steadily throughout older adulthood. Studies report urinary incontinence in one-third of women aged 60 to 90.
Prevalence estimates vary by region, ranging from 1.8 to 30.5 percent in Europe, 1.7 to 36.4 percent in the United States and 1.5 to 15.2 percent in Asia.
Global aging trends are rapidly accelerating.
In the United States, 17 percent of the population was over 65 in 2020.
In Europe’s Big 5 countries, the percentage of adults over 60 is expected to reach between 25 and 42 percent by 2050.
China’s population over 60 is projected to exceed 30 percent by 2030.
Japan is one of the oldest populations in the world, with one-third of residents expected to be 65 or older by 2040.
Brazil’s population aged 60 and older is expected to reach nearly 34 percent by 2060.
Russia is also aging but at a slower pace.
As these demographic shifts unfold, the number of patients requiring both non-surgical and surgical incontinence treatments will grow substantially. This will increase demand for urethral bulking agents, male implantable devices, female slings and urinary bags.
Active Lifestyles
While urinary incontinence is most common in adults over the age of 50, a rising number of younger patients are being diagnosed. Changes in lifestyle, childbirth patterns, pelvic floor injuries, sports participation and increased awareness all contribute to higher diagnosis rates.
Many patients prefer solutions that allow them to maintain active lifestyles. Absorbent pads are not suitable for long-term use among active individuals. As a result, demand for minimally invasive treatments such as urethral bulking agents and selected implantable devices continues to increase.
Male external catheters, female slings and minimally invasive bulking agents are preferred by patients who want to remain active without prolonged recovery times. This trend is expected to strengthen as more patients prioritize mobility and quality of life.
Growth of Urethral Bulking Agents
Urethral bulking agents are minimally invasive treatments that provide a viable alternative to slings for both male and female patients. These procedures can be performed quickly and do not require mesh, which is important for patients concerned about implantable materials.
Bulkers have gained interest due to concerns surrounding vaginal slings, regulatory actions and public attention to implant safety. As patient and clinician awareness increases, bulking agents are expected to experience strong growth and take share from sling procedures in certain markets.
Market Limiters
Regulatory and Reimbursement Changes
The urinary incontinence device market has been significantly affected by litigation, product recalls and regulatory scrutiny. These factors have impacted sling procedures most severely.
Notable examples include:
In 2017, a class action suit was launched in Australia against Johnson & Johnson and Ethicon concerning transvaginal mesh.
More than 5,000 lawsuits regarding transvaginal mesh remain pending globally.
In 2018, the Australian Register of Therapeutic Goods removed transvaginal mesh for pelvic organ prolapse repair and mini-slings from the market. This included Solyx and Altis devices.
In July 2018, the NHS suspended the use of urinary incontinence slings, reducing demand significantly in the United Kingdom and raising global awareness.
These developments led many clinicians to take a more conservative approach to sling selection, which slowed procedure volumes and decreased market growth across several European regions.
Procedural Limitations
Female sling procedures involve surgical intervention, including insertion of mesh material that may complicate future childbirth. Active patients who cannot commit to six to eight weeks of recovery may choose bulking agents, radiofrequency treatments or laser devices instead of sling surgery.
Male sling and artificial urinary sphincter procedures also require recovery time and patient training, which may limit adoption among certain patient groups.
Autologous Pubovaginal Slings
Some patients prefer to avoid synthetic mesh entirely. In these cases, surgeons may harvest autologous tissue from the patient’s abdomen and use it as a sling. This eliminates concerns about mesh implants but increases procedure complexity and cost.
Autologous procedures reduce the use of synthetic sling products and create a natural alternative that shifts some procedural volume away from commercial sling devices.
Market Coverage and Data Scope
Quantitative Coverage
Market size
Market shares
Market forecasts
Growth rates
Units sold
Average selling prices
Qualitative Coverage
Growth trends
Market limiters
Competitive analysis and SWOT
Company profiles and portfolios
Mergers and acquisitions
FDA recalls and regulatory developments
Disruptive technologies
Disease and demographic overviews
Time Frame
Historical data from 2021 to 2024
Base year 2024
Forecasts to 2031
Data Sources
Primary interviews with urologists and gynecologists
Government physician and hospital datasets
Regulatory filings
Hospital private data
Import and export data
iData internal modeling and procedure databases
Markets Covered and Segmentation
Urethral Bulking Agent Market
Female Urinary Incontinence Sling Market
Transvaginal tape slings
Transobturator slings
Single-incision slings
Male Implantable Device Market
Male incontinence slings
Artificial urinary sphincters
Urinary Bag Market
Bedside bags
Leg bags
Competitive Analysis
Boston Scientific
Boston Scientific was the leading competitor in the global urinary incontinence device market in 2024. The company held top positions in both urethral bulking agents and female incontinence slings. Boston Scientific’s leadership reflects a broad product portfolio, strong branding and continued investment in products that support minimally invasive therapy. The company’s innovations and market reach have helped maintain its position across major regions.
Coloplast
Coloplast held the second-largest share of the total market in 2024. Coloplast offers a wide range of female urinary slings such as Aris and Altis, as well as the Virtue male sling. The company is active in both male and female implantable incontinence devices and has a strong reputation for quality and clinical training support. Coloplast has a sizable presence across Europe and North America, contributing to its global position.
Ethicon
Ethicon was the third-leading competitor and maintained a strong presence in the female urinary sling market. Following the closure of Astora, Ethicon expanded its leadership position in female sling products and remains a key supplier. Ethicon does not participate in the male implantable device market but remains influential in female procedures due to its broad distribution network and established product line.
Technology and Practice Trends
Key trends shaping the urinary incontinence device market include:
Increasing adoption of minimally invasive bulking agents as an alternative to mesh slings
Continued use of slings where regulatory frameworks allow, with gradual shifts to slings with improved safety profiles
Broader availability of male external and implantable devices for men who desire improved quality of life
Growth of compact urinary bags designed for discreet daily use
Higher focus on patient-centered solutions, including devices that support active lifestyles
Increased reliance on autologous slings in specific patient populations concerned about synthetic mesh
Technology improvements in bulking agents, including longer-lasting injectable materials
Market developments continue to reflect patient preference for comfort, reduced recovery time and long-term treatment efficacy.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Why This Report
Which urinary incontinence segments will grow fastest through 2031
How demographic aging and lifestyle trends are reshaping global demand
What impact regulatory actions have had on sling procedure volumes
How urethral bulking agents are positioned to gain share as alternatives to mesh
Which competitors hold the strongest positions and why
How reimbursement and product safety concerns will shape future market adoption
Where global regions differ in clinical practice and purchasing decisions
This report supports strategic planning, product development, market entry and competitive analysis within the urinary incontinence device sector.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows.
Table of Contents
263 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
